Waldencast Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated July 30, 2026, reports the completion of the sale of Waldencast Plc's Obagi Medical dermatological skincare and aesthetics business. The transaction was executed pursuant to a Purchase and Sale Agreement dated June 1, 2026.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period. The primary financial disclosure relates to the transaction consideration:
- Total Consideration: Up to $460,000,000, subject to customary adjustments for cash, indebtedness, working capital, and expenses.
- Fixed Vendor Note: $10,000,000 principal amount.
- Adjustable Vendor Note: $20,000,000 principal amount.
- Contingent Consideration (Earnout): Up to $64,000,000 based on non-injectables revenue milestones for fiscal year 2026 and injectables revenue milestones for fiscal year 2027.
Material Changes
The most significant material change is the divestiture of the Obagi Medical business. Additionally, the Company experienced a major leadership transition effective at the close of business on July 30, 2026:
- Departures: Michel Brousset (CEO), Hind Sebti (Chief Growth Officer), and Manuel Manfredi (CFO) transitioned to lead the newly sold Obagi Medical entity.
- Appointments: Felipe Dutra, previously Chairman of the Board, was appointed Executive Chairman and will serve as the principal executive officer and principal financial officer.
Outlook, Risks, and Contingencies
Management indicated that the departing executives will provide services during a transitional period. The filing includes standard forward-looking statements regarding the intended benefits of the transaction and future strategies. Key risks and contingencies identified include:
- Failure to realize anticipated transaction benefits on the expected timeline.
- Reduction in total consideration if earnout milestones are not achieved or due to adjustments related to Vendor Notes.
- Operational challenges in managing the business without the departing executives.
- Geopolitical events, economic conditions, and foreign exchange fluctuations.
Investor Verification Checklist
- Verify the final purchase price after customary closing adjustments (cash, debt, working capital).
- Confirm the specific revenue milestones required to trigger the $64,000,000 earnout payments.
- Review the transitional service agreements for the departing executives to understand the scope and duration of their continued involvement.
- Assess the Company's remaining business portfolio and strategic direction under the new leadership of Felipe Dutra.
- Examine the full text of the Purchase and Sale Agreement (Exhibit 2.1 to the June 1, 2026 Form 6-K) for detailed covenants and conditions.